Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Naseem Buckley of Genentech will speak at Pharmica's SharePoint Conference for the Life Sciences Industry on September 30th and October ... Benzinga.com, 20 hours ago
Priority review for Avastin - Seeking Alpha, 2 days ago
Priority Review For Genentech's Avastin - American Journal of Managed Care, 2 days ago
A Phase II clinical trial for Genentech's investigational Alzheimer's drug failed to meet its primary endpoints but the company and campaigners have pointed to a possible chink of light in the results. The data on amyloid antibody agent ...Pharmafocus, 6 days ago Mixed results for Genentech Alzheimer's drug San Francisco Chronicle, 1 week ago Genentech's Alzheimer's drug has mixed results in trials San Francisco Chronicle, 1 week ago Should Roche's Failed Trial Give Hope To Alzheimer's Patients? BioSpace, 1 week ago
Genentech has announced that its phase 3 coBRIM study, evaluating the safety and efficacy of a combination of cobimetinib and vemurafenib for the treatment of melanoma, has met its primary endpoint. Genentech, a Roche company, studied the ...Dermatology Times, 1 day ago Genentech's Phase III melanoma study meets primary endpoint Individual.com, 1 week ago
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass., July 22, 2014 /PRNewswire/ — Decision Resources ...Red Orbit, 1 day ago
Study Results from Genentech, Inc. Update Understanding of Neutral Amino Acids (An allosteric switch for pro-HGF/Met signaling using zymogen...
Study Results from Genentech, Inc. Update Understanding of Neutral Amino Acids (An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides) By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish ...4 Traders, 1 day ago
Findings from Genentech, Inc. in the Area of Chemotherapy Described (B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous...
Findings from Genentech, Inc. in the Area of Chemotherapy Described (B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas) By a News Reporter-Staff News Editor at Biotech Week -- A new study on Drugs and ...4 Traders, 1 day ago Studies from Genentech, Inc. Add New Findings in the Area of Basal Cell Cancer (Systematic Review of Vismodegib Toxicity Profile in the Treatment of... 4 Traders, 1 week ago
Investigators at Genentech, Inc. Discuss Findings in Rheumatoid Arthritis (Patients' Willingness to Trade Off Between the Duration and Frequency of...
Investigators at Genentech, Inc. Discuss Findings in Rheumatoid Arthritis (Patients' Willingness to Trade Off Between the Duration and Frequency of Rheumatoid Arthritis Treatments) By a News Reporter-Staff News Editor at Health & Medicine Week -- ...4 Traders, 1 day ago
ARVO Foundation Invites Applications for Genentech Age-Related Macular Degeneration Research Fellowships
Deadline: September 30, 2014 The ARVO Foundation for Eye Research , the philanthropic arm of the Association of Research in Vision and Ophthalmology , is inviting applications for two Genentech Age-Related Macular Degeneration Research ...Philanthropy News Digest, 2 days ago
Genentech it didn't already own for $47 billion. Since then, Roche has racked up a series of smaller pharma and biotech buyouts, mostly aimed at restocking its pipeline as its olderBig News Network, 3 days ago Roche CEO: No appetite for expensive megadeals here FiercePharma, 3 days ago Takeovers ruled out Gulf Daily News, 5 days ago Roche CEO plans to steer clear of big acquisitions Reuters UK, 5 days ago
The week started amid anticipation of a new round of public debuts, with six of the 11 companies queued up coming from the life sciences, according to Renaissance Capital. Then on Tuesday, the Federal Reserve singled out two sectors as overvalued: ...Xconomy, 6 days ago
on your WebpageAdd Widget >Get your members hooked!